Paper Review Records
All Paper Review Records
11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
163
days
ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab
Authors
Henrik Horndalsveen; Vilde Drageset Haakensen; Tesfaye Madebo; Bjørn Henning Grønberg; Tarje Onsøien Halvorsen; Maria Moksnes Bjaanæs; Britina Kjuul Danielsen; Mari Børve; Solveig Kokkvoll; Tonje Sofie Dalen Boda; Åsa Kristina Öjlert; Åslaug HellandShow moreShow less
Affiliations
Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospital, Oslo, Norway; Department of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Pulmonology, Stavanger University Hospital, Stavanger, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NorwayShow moreShow less
43
days
First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
Authors
Leonardo Brunetti; Giacomo Colella; Giuseppina Rita Di Fazio; Giulia La Cava; Valentina Santo; Federica Pecci; Julia K. Rotow; Jessica R. Bauman; Amin H. Nassar; Elio Adib; Abdul Rafeh Naqash; Marco Tagliamento; Roberto Ferrara; Fabrizio Citarella; Marco Russano; Biagio Ricciuti; Corinne Faivre-Finn; Lizza E.L. Hendriks; Antonio Passaro; Bruno Vincenzi; Fabian Acker; Lisa Derosa; David Planchard; Hugo J.W.L. Aerts; Silvia Novello; Francesco Passiglia; Carlo Greco; Sara Ramella; Alessio CortelliniShow moreShow less
Affiliations
Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy; Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; GROW Research Institute for Cancer and Reproduction, Maastricht University, Maastricht, The Netherlands; Department of Surgery and Cancer, Imperial College of London, London, United Kingdom; Medical Oncology, ASST Fatebenefratelli-Sacco, Milano, Italy; Department of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts; Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy; IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom The Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Pulmonary Diseases, GROW—Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy; Department of Medicine II, Hematology and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany; Tumor Immunology and Cancer Immunotherapy, Université Paris-Saclay, Gustave Roussy, Inserm UMR1015, Villejuif, France; Department of Medical Oncology, Gustave Roussy, Villejuif, France; Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France Faculty of Medicine, Paris-Saclay University, Paris, France; Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Harvard Institutes of Medicine, Boston, Massachusetts; Radiology and Nuclear Medicine, CARIM and GROW, Maastricht University, Maastricht, The Netherlands; Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy; Operative Research Unit of Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, ItalyShow moreShow less
171
days
YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC
Authors
C. Allison Stewart; Kavya Ramkumar; Runsheng Wang; Yuanxin Xi; Alexa Halliday; Lixia Diao; Qi Wang; Alejandra Serrano; Sarah Groves; Simon Heeke; Azusa Tanimoto; Laura Kaiser; Whitney Lewis; Mukulika Bose; Pedro Rocha; Loukia Karacosta; Vito Quaranta; Jing Wang; Julie George; Luisa Maren Solis Soto; Bingnan Zhang; John V. Heymach; Lauren A. Byers; Carl M. GayShow moreShow less
Affiliations
Department of Thoracic/Head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia; Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Medical Oncology, Thoracic Tumors Unit, Vall d’Hebron University Hospital, Barcelona, Spain; Institute for Experiential AI, Northeastern University, Boston, Massachusetts; Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine and University Hospital Cologne, University Hospital of Cologne, Cologne, GermanyShow moreShow less
109
days
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial
Authors
Suresh Senan; Byoung Chul Cho; Konstantin K. Laktionov; Yoshitaka Zenke; Ki Hyeong Lee; Qiming Wang; Alejandro Navarro; Eva Lotte Buchmeier; Sema Sezgin Goksu; Andrzej Badzio; Anhui Shi; Davey B. Daniel; Milada Zemanova; Puneeth Iyengar; Luis Paz-Ares; Leah Szadkowski; Priti Chugh; W. Victoria Lai; David R. SpigelShow moreShow less
Affiliations
Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia; National Cancer Center Hospital East, Kashiwa, Japan; Chungbuk National University Hospital, Cheongju, Republic of Korea; The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China; Hospital Vall d'Hebron and Vall d’Hebron Institute of Oncology, Barcelona, Spain; Hospitals of the City of Cologne gGmbH, Cologne, Germany; Akdeniz University Medical Faculty, Antalya, Türkiye; Medical University of Gdansk, Gdansk, Poland; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China; Tennessee Oncology PLLC, Nashville, Tennessee; First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic; Memorial Sloan Kettering Cancer Center, New York, New York; Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain; AstraZeneca, Mississauga, Ontario, Canada; AstraZeneca, Waltham, Massachusetts; AstraZeneca, New York, New York; Sarah Cannon Research Institute, Nashville, TennesseeShow moreShow less
62
days
Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group
Authors
Aaron C. Tan; Bin-Chi Liao; Molly Li; David Lee; Yuji Uehara; Lucksamon Thamlikitkul; Jia-Tao Zhang; Meimei Zheng; Chee Khoon Lee; Nick Pavlakis; Thomas John; Ross A. Soo; Anders Skanderup; Pei Jye Voon; Beung-Chul Ahn; Sehhoon Park; Hidetoshi Hayashi; Yasushi Goto; Hidehito Horinouchi; Yasushi Yatabe; Thanyanan Reungwetwattana; James Chih-Hsin Yang; Dong-Wan Kim; Tony Mok; Daniel S.W. Tan; Yi-Long Wu; Myung-Ju AhnShow moreShow less
Affiliations
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China; Sunway Medical Centre, Kuala Lumpur, Malaysia; Department of Thoracic Oncology, National Cancer Centre Hospital, Chuo-ku, Tokyo, Japan; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore; Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore; Department of Radiotherapy, Oncology and Palliative Care, Hospital Umum Sarawak, Kuching, Sarawak, Malaysia; Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, Research Institute and Hospital, National Cancer Center, Gyeonggi-do, Republic of Korea; Department of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan; Department of Diagnostic Pathology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Internal Medicine, Seoul National University Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of KoreaShow moreShow less
110
days
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial
Authors
Benjamin Levy; Luis Paz-Ares; Chien-Chung Lin; Scott Herbert; Tsung-Ying Yang; Anthony Tolcher; Yanyan Lou; Yoshitaka Zenke; Diego Cortinovis; Enriqueta Felip; Manuel Domine; Konstantinos Leventakos; Emiliano Calvo; Atsushi Horiike; Edward Pan; Priyanka Basak; Daisy Lin; Wen Gu; Rachel Chiaverelli; Michael J. Chisamore; Yasushi GotoShow moreShow less
Affiliations
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, Maryland; Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense & CiberOnc, Madrid, Spain; Department of Internal Medicine, National Cheng Kung University Hospital and Tainan Hospital, Ministry of Health and Welfare, Tainan City, Taiwan; Quantum, Santa Fe, New Mexico; Department of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; NEXT Oncology, San Antonio, Texas; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; Medicine and Surgery Department, University of Milano-Bicocca, Milano, Italy; Vall d’Hebron Hospital Campus, Vall d’Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Spain; Department of Oncology, Hospital Universitario Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain; Department of Oncology, Mayo Clinic, Rochester, Minnesota; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan;; Daiichi Sankyo, Inc., Basking Ridge, New Jersey; Oncology Early Development – External Collaborations, Merck & Co., Inc., Rahway, New Jersey; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, JapanShow moreShow less
FAQ
How long does Journal of Thoracic Oncology take to review a manuscript?
As of 2026-11-19, CrushSCI has 11 complete review records for Journal of Thoracic Oncology. The fastest paper went from submission to acceptance in 12 days (Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay, received 2026-01-27, accepted 2026-02-08); the slowest took 245 days. The average is 103.9 days and the median is 99 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
